Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
3 big reasons why Sorrento share price will increase dramatically.
1. ABIVERTINIB global $61 billion market partnership(s). This will be a multi-billion, worldwide, upfront, milestone and royalty deal. This alone will fund Sorrento's other 75 programs.
2. COVISTIX revenue stream. Sales are being recorded in Q4 of 2021 and will dramatically increase in Q1 of 2022. Europe, Central and South America, Canada and Japan will soon be on stream. Even the US may catch up!
3. In Q1 of 2022 there will be important trial results from COVI-AMG, COVIDROPS, COVI-MSC, SP-102 and ABIVERTINIB(NSCLC). There could be several more EUA's and marketing could begin for SP-102 and ABIVERTINIB in 2H of 2022.
Investors say "SHOW US THE MONEY"...and that will happen big time in 2022!
I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's are producing revenue in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. Giant ABIVERTINIB centered partnership(s) coming soon! And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
The ABIVERTINIB partnership(s) will be the company maker! And with a steady and increasing flow of COVISTIX income investors will see a bluesky potential small biotech with a solid financial base...a very uncommon creature!
2 big reasons why most small biotech stock prices have declined.
1. Sector Rotation. Biotechs were very high early in the year. They are now such bargains that their share prices will soon move up!
2. Tax Loss selling. Most tax loss selling has already occurred. Most sellers want to be able to repurchase(after 30 days) to share in the expected January market rise.
3 big reasons why Sorrento share price will increase dramatically.
1. ABIVERTINIB global $61 billion market partnership(s). This will be a multi-billion, worldwide, upfront, milestone and royalty deal. This alone will fund Sorrento's other 75 programs.
2. COVISTIX revenue stream. Sales are being recorded in Q4 of 2021 and will dramatically increase in Q1 of 2022. Europe, Central and South America, Canada and Japan will soon be on stream. Even the US may catch up!
3. In Q1 of 2022 there will be important trial results from COVI-AMG, COVIDROPS, COVI-MSC, SP-102 and ABIVERTINIB(NSCLC). There could be several more EUA's and marketing could begin for SP-102 and ABIVERTINIB in 2H of 2022.
Investors say "SHOW US THE MONEY"...and that will happen big time in 2022!
What was todays EVERCORE conference all about if retail investors couldn't connect? EVERCORE is a global banking and advisory firm who consult on mergers and acquisitions. Guess what Sorrento is doing?
Answer! Seeking major global partnership(s) to co-develop and co-commercialize a $61 Billion market Abivertinib centered pipeline for Cancer, Covid and Auto-immune indications!
Will retail investors learn more this month or will we learn more at the early January... 30 minute presentation at a H.C.Wainwright Conference?...or both?
There is rustling in the swamp! We have been warned about some big news coming!
The new COVISTIX website is designed for the worldwide market. Under "Customer Support" note that the "Instructions for Use" are available in English, Spanish, French, German, Italian, Portugese and Japanese!
It was 6 months ago that Sorrento stated that they would seek "...major global partnership(s) to co-develop and co-commercialize ABIVERTINIB."
The "TEASER" outlining the potential $61 Billion market just lets the public in on what the partnership discussions have been about!
We now know that the partnership(s) will be...
GLOBAL, CO-DEVELOPMENT, CO-COMMERCIALIZATION and about CANCER, COVID and AUTO-IMMUNE indications!
$61 Billion market size is huge.
THE DEAL WILL BE VERY BIG!
I wonder if Merck might want to enter a bidding war for Abivertinib?
Their anti-viral has been disappointing as one poster pointed out...
"The very close and divided 13-10 FDA panel vote for MRK's covid pill gives me great optimism given that MRK's covid pill only had a modest 30% efficacy rate and a questionable safety profile. Reminds me of Aduhelm's weak and questionable approval and you know how that turned out for BIIB."
This is a very good point and Abivertinib, COVI-MSC, COVI-AMG and COVIDROPS should interest them greatly! As a partner their influence with the FDA and marketing muscle would be very helpful.
Abivertinib's $61 Billion market in Covid,Cancer and Auto-immune indications will interest many Big Pharmas . And Merck will be one of them IMO!
On November 29, 2021 Sorrento published a "Teaser" to be used in partnering talks focused on Abivertinib "...a Broad Pipeline for Cancer, COVID-19 and autoimmune diseases ($61 B market)".
This should be no surprise to anyone as on June 2, 2021 Sorrento stated that it would seek "....major global partnership(s) to co-develop and co-commercialize Abivertinib."
What should be apparent to all shareholders is that any Big Pharma interested in a global partnership focused on Abivertinib, would also be interested in a global partnership involving Sorrento's entire Cancer, COVID-19, autoimmune and non-opioid pain portfolios.
I look for any partnership(s) to be a signal as to who will eventually buyout Sorrento! Merck, Pfizer, J and J ... every Big Pharma with declining pipelines would love to have the inside track to acquire Sorrento. Look for a multi-Billion upfront payment followed by multi-Billion milestones and double digit royalties and co-development and co-commercialization.
THIS IS A BIG DEAL!
Latest version of Sorrento Therapeutics Boom List
1.Sorrento partner with Dyadic to licence DYAI-100 as a cheap alternative to other Vaccines and reveal it elicits strong immune responses against Covid and multiple major variants of concern
2.Covistix approved in Mexico and Brazil and EU- First order of 25m tests shipped July 21. 5m kits sold Nov 21- Expecting large revenues, Canada and US to follow. Ji confirmed they can make 50 million tests per month and orders are waiting. www.covistix.com appeared on a live website and looks ready for US sales. Independent study shows Covistix to have superior sensitivity to leading brands. Listed for sale on Mex website $8 US per test. 10Q Shows lease on massive distribution center.
3.COVISHIELD Ramping up development in partnership with Mount Sinai.
4.COVI-MSC- Phase 1b tests complete 10/10 patients recovered from mechanical ventilation and leaving hospital after a week!!! Phase 2 PIVOTAL Approved in Brazil May 2021
5.Fortune Bio (Sorrento Manufacturer in China) Confirmed Covi-Stix being made with CE approval certificate. This and Respi-Stix listed for sale. http://www.fortunetest.com/. Setting up manufacturing in US and moving Fortune Bio Technology to fulfil this. Confirmed in a job description and shipping forms.
6.RESPI-STIX combination test for viruses including Covid, Flu A and B
7.Covi-Trace application submitted- Brunswick mentioned they are submitting a low nasal swab version
8.DARPA funding of at least $34m to bring STI 2020 to the end of P2 trials and beyond. Three phase 2 trials of COVI-AMG being delivered to 1000 patients. STI2020 is a refined version of 1499 with increased potency and requires smaller dosage. AKA Covi-Drops
9.Multi-year deal with the U.S. Naval Medical Research Unit initially using Covi-Stix, Track, Drops and AMG announced June 2021” This will rapidly and efficiently deploy our products in all parts of the world”
10.Abivertinib, Cures Covid at late stages. P2 Complete - impressive readout but PR bungled. P3 Imminent
11.Covi-Drops STI2099 (Refined version of 1499) nasal antibody spray. PH2 trial in the UK 350 Patients dosing started. PH2 in the US also underway recruiting 1800 patients.
12.Sorrento Therapeutics entered into an Exclusive Licensing Term Sheet with Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome- Ph2 already approved to proceed. Also ARD-101 collaboration on obesity drug Ph2 Q4 ‘21
13.Testing Lab approved in California for Covid (will speed up in house testing and provide source of revenue)
14. Covid programs in progress with strong potential- T-VIVIA-19 combination vaccines in development
15.ACEA owned- full ownership of Abivertinib, multiple pipeline additions and a large manufacturing facility.
16.Kelun, Phase I Study of A166, for Breast Cancers released positive results Jun 21. (Licence)
17.Sofusa DoseConnect multiple Ph1b trial extended Aug 21 to test lower dosage as current dose showed “quite remarkable improvements” after 10 weeks. Drug already approved – this is all about the delivery. Multiple drugs can be dosed this way and used to extend patents! June 2021 1b trial delivery patients with Melanoma- first of many with Mayo C.
18.Manufacturing of testing to be brought in house leveraging Bioserve potentially instead of ANP acquisition
19.Lee’s Pharmaceutical Anti-PD-L1 Antibody Socazolimab, licensed from Sorrento Breakthrough designation. Multiple P3 trials underway for approval in China.
20.Sorrento Partner Mabpharm has Received Marketing Approval in China for Infliximab Biobetter. Sorrento holds licence for rest of world and working with FDA on equivalence. $4.2 billion global market.
21. Last year we acquired multiple companies. We own 18% of Celulatory
22. STI-6643 Ph1 Trial approved for multiple cancer type treatments “Basket Trial”
23. Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Haematological Malignancies and Solid Tumours Based on an Exclusive Technology License from the Mayo Clinic- Multiple IND’s in 2021- April 2021 FDA Clearance to Proceed with Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
24. Institutions buying in and own 26% of stock: BlackRock 6.4% Vanguard 4.5% and State Street 3.3%
25. Multiple cancer and pain relief plays which triggered BO offers excess of $7 in 2019 before Covid started
26. One drug approved (ZTildo) and sales are growing massively (33 million more potential patients Aug 21)
27. Immunity Bio and NK merger completed resulting in us owning 8.19m shares in $IBRX. PSS is chairman of NK. Expecting $1bn in stock or cash as part of the settlement for Cynviloq case Post arbitration set for November 30. We sold for over $100m
28. Four analysts have us at $20-35 which is very conservative.
29. CEO only gets share options if he maintains SP above $17-130 for six consecutive months
30. We have been heavily shorted due to a scam by Hindenburg (top 30 most shorted) and perhaps PSS manipulating the price. We are poised for a massive short squeeze.
31. SP-102 Ph3 trial fully enrolled - first FDA approved epidural steroid product for the treatment of sciatica by Jan 2022 Top line results due. Ph2 saw 100% of patients with at least 50% pain improvement.
32. RTX Ph3- Non Opioid treatment for Arthritis/Cancer pain, trial approved Q4 2021. P1b results v positive
33. NDA in China for Abivertinib for NSCLC expecting the same in the US this year
34. Significant recruitment in manufacturing roles and warehouse facilities.
35. July 2021, Sorrento lease a massive new facility next to HQ. Clear indication of manufacturing contracts
36. At WuXi HF Ji mentioned antibody cocktail will target all Covid and potentially ALL Viruses including HIV
37. Speculation of buyout growing credence with multiple products moving towards approval
Jess my guess is that it will detect omicron. There are many variants to come. Over 60 million unvaccinated Americans and 80-90% unvaccinated in many poor countries. Cheaper, better longer lasting vaccines are still needed. Plus all of Sorrento's therapeutics!
7 major indications with $60.6 Billion combined market size...can you say huge partnership(s)!
NEW 11 slide ABIVERTINIB presentation...amazing franchise oral drug!
https://investors.sorrentotherapeutics.com/static-files/22057ad8-3752-4ee7-a4de-b84a055c0764
Jess...I can't recall that specifically...but Sorrento has mentioned at least 3 anti-Covid vaccines and 3 anti-virals. Some of these should reach the clinic very soon as they have all been in pre-clinical studies.
MARKET SPOOKED BY COVID VARIANTS? SORRENTO HAS THE ANSWERS!
STIX / ABIVERTINIB / COVI-AMG / COVIDROPS / COVI-MSC
All have near term news. All have billion dollar markets. And SP-102 and ABIVERTINIB cancer news coming!
The other 72+ Sorrento programs can be financed by the profits from these programs alone. I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
S
UPDATE! The Brazilian COVI-MSC 100 patient double blinded study of hospitalized ARDS patients IS NOW RECRUITING in 6 hospitals.
PRIMARY COMPLETION in DECEMBER 2021
FINAL COMPLETION in FEBRUARY 2022
"This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress syndrome.
COVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4.
Acceptable standard of care treatments for COVID-19 include all approved or emergency use authorized treatments for COVID-19, even if used off-label.
Study Design
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Treatment of COVID-19-Induced Acute Respiratory Distress: A Phase 2 Study of Intravenous Administration of Allogeneic Adipose-Derived Mesenchymal Stem Cells
Actual Study Start Date : November 16, 2021
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : February 2022
Yes both are MSC drugs...and both are derived from fat cells!
These results are from a very small study...but they support the COVI-MSC potential. COVI-MSC is now in larger studies. I expect this Israeli drug will be required to do do larger studies.
There is a lot of news due in coming days, weeks and months!
We will receive the phase 3 SP-102 data in January. This should lead to SP-102 marketing in 2H of 2022. Sciatica and lower back pain are multi-billion dollar markets! The marketing teams are already being hired.
We should also expect news soon about Abivertinib marketing approval for NSCLC in China and a NDA application in the US. Abivertinb use against cytokine storm could also earn an EUA in Brazil, Mexico and the US at any time.
And worldwide marketing partners for COVISTIX and Abivertinib in cancer and cytokine storm could be announced soon. These worldwide partnerships could also be extended to COVI-AMG, COVIDROPS and COVI-MSC once they achieve EUA status. These are all in phase 2 status and interim analysis can be expected both for safety and efficacy. Many EUA's have been granted at this stage. Brazil, Mexico the UK , Europe and the US should all be interested.
No vaccine is 100% effective. For example the measles vaccine has saved many lives but is not 100% effective. And because of widespread vaccination in the US measles is very rare ... however those who travel to largely unvaccinated parts of the world can bring it back to the US.
Here is what the CDC says about the measles vaccine.
Measles Vaccination
Pronounced (MEE-zills)
"Measles is a very contagious disease caused by a virus. It spreads through the air when an infected person coughs or sneezes. Measles starts with a cough, runny nose, red eyes, and fever. Then a rash of tiny, red spots breaks out. It starts at the head and spreads to the rest of the body.
Measles can be prevented with MMR vaccine. The vaccine protects against three diseases: measles, mumps, and rubella. CDC recommends children get two doses of MMR vaccine, starting with the first dose at 12 through 15 months of age, and the second dose at 4 through 6 years of age. Teens and adults should also be up to date on their MMR vaccination.
The MMR vaccine is very safe and effective. Two doses of MMR vaccine are about 97% effective at preventing measles; one dose is about 93% effective.
Children may also get MMRV vaccine, which protects against measles, mumps, rubella, and varicella (chickenpox). This vaccine is only licensed for use in children who are 12 months through 12 years of age.
Before the measles vaccination program started in 1963, an estimated 3 to 4 million people got measles each year in the United States. Of these, approximately 500,000 cases were reported each year to CDC; of these, 400 to 500 died, 48,000 were hospitalized, and 1,000 developed encephalitis (brain swelling) from measles. Since then, widespread use of measles virus-containing vaccine has led to a greater than 99% reduction in measles cases compared with the pre-vaccine era. However, measles is still common in other countries. Unvaccinated people continue to get measles while abroad and bring the disease into the United States and spread it to others."
As I have travelled around the world many times I have received many vaccinations for many deadly diseases...and I have received the Covid vaccine 3 times! I recommend it. And I also recommend the highly effective, but imperfect Shingles vaccine! We are very blessed to have these available!
I am very glad to see Sorrento help develop more effective Covid vaccines which are are also cheaper and more accessible to the third world nations. Those along with Sorrento's many therapies can save many lives!
In both trials I would expect an interim analysis for both safety and efficacy. The independent committee doing this analysis could recommend the trial be concluded early because of overwhelming safety and efficacy. Depending on the speed of enrollment this could happen in both trials in Q1 2022.
What can Sorrento investors expect in terms of marketing partnerships? Looking at recent job recruitments I expect Sorrento to market its Covid, pain and cancer portfolios itself in the US and in much of South America (eg.Sorrento Mexico).
Sorrento already has many cancer partnerships in China's rapidly growing market and I expect more to come. Sorrento already has ACEA's Chinese assets as a base.
Sorrento has already announced that it is looking for marketing partnerships outside of China for Abivertinib and that likely signals the same could follow for the rest of its very large cancer portfolio. The same marketing partners could also handle the Covid and pain portfolios.
Multi-billion marketing giant Cardinal Health appears to have the inside track. It is listed as a marketing partner for the pain portfolio(through Scilex)and it has an outreach into 59 different nations.
Let's hope that Sorrento strengthens its shareholders relations activity and informs us of its worldwide strategy as it takes these important marketing partnerships steps towards building a $200-300 billion market cap corporation!
Sorrento is looking for sales managers for Antibody Drug Conjugates (ADC). What are ADCs?
"Antibody-drug conjugates (ADCs) are targeted immunotherapies that utilize potent cytotoxic drugs conjugated to antibodies via chemical linkers. This increases the efficacy of chemotherapeutic agents by effectively targeting the drug directly to cancer cells. Thus, ADCs also have reduced side effects because targeting the cancer cells means less of the cytotoxic drug will enter healthy cells.
Sorrento’s next generation ADC technology platform utilizes innovative conjugation methods to produce stable ADCs by linking the toxin to only specific, preselected sites of an antibody; the resulting ADCs have shown high anti-tumor efficacy in preclinical studies." Sorrento has mentioned ...
CD38 ADC
Trop2 ADC
BCMA ADC
and half a dozen Mayo Clinic ADNAB ADCs. Some are in phase 1 and some ADNAB are in phase 2.
Apparently many people post on stock websites as an inexpensive form of self therapy. Does it work? Who knows? I just wish these stock boards allowed us to block more than a handful! Sadly very few share scientific or medical insights.
What kind of cancer is caused by KRAS mutations?
KRAS drives 32% of lung cancers, 40% of colorectal cancers, and 85% to 90% of pancreatic cancer cases. A lot of unmet needs!
Sorrento has been granted a patent for anti-KRAS antibodies. This is a big deal as KRAS gene mutation is INVOLVED IN 33% OF HUMAN CANCERS!
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5081&f=G&l=50&d=PTXT&p=102&S1=20211116&OS=20211116&RS=20211116
STIX / ABIVERTINIB / SP102 / DROPS
All have near term news. All have billion dollar markets.
The other 72+ Sorrento programs can be financed by the profits from these 4 programs alone. I was glad to see the new updated corporate presentation. https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
And big funds are buying shares! Blackrock 20.8 million:Vanguard 15.5 million:State St. 12.3 million.
***PHASE 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered.China NDA filed for cervical cancer.
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar(approved in China. SRNE holds ROW rights!)
7. SP-102 sciatica + back pain. Marketing in 2H 2022.
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico, Brazil and Europe...millions shipped to Mexico. WHO and Canada coming soon. DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel phase 1b
13. Cynviloq (part of PSS lawsuit)
***PHASE 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS phase 2 US, UK and Mexico. EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential to prevent intubation Brazil and US.
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
***PHASE 1, IND filed or pre-IND (46+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T ph.1
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 IND granted in China...partnered.
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. Covid mRNA vaccine(Sofusa delivery)
38.low cost C1 based multivalent vaccine(rights to 60% of world population)...can this deal be expanded?
39. Salicyn-30 oral antiviral
40.MP18 oral antiviral MPro inhibitor
41.Combination oral antiviral drug cocktail
42.RESPISTIX Combination Covid/seasonal flu tests
43.Combination Covid/seasonal flu vaccine
44 advanced Animal Health subsidiary
45. 1,000,000+ small molecule library
46. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has millions of shares of Celularity and ImmuneOncia. These are worth many hundreds of millions and the PSS binding arbitration could be settled with very large potential gains. It has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks in Mexico. Outstanding ABIVERTINIB(COVID) results in Brazil and US. And SP-102 sales will begin in 2022 with multi-billion potential. Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma!
Beautiful new November presentation!
https://investors.sorrentotherapeutics.com/static-files/f9f8b12e-6037-4b48-b919-6d99d417698a
There are two distinct groups of posters on the Sorrento boards.
One group is here for the science. They love what Sorrento is doing to combat Covid, cancer and pain. They feast on the November presentation and look forward to more news on COVISTIX, COVI-AMG, COVIDROPS, COVI-SHIELD, ABIVERTINIB, COVI-MSC, SP-102, SP-103, SP-104, RTX, ADC's, DAR-T, ADC's etc.
https://investors.sorrentotherapeutics.com/events-and-presentations/presentations
The second group are here to play games. They want to make short term gains by playing on inexperienced investors impatience with the clinical trials process that all pharmaceuticals must pass through. COVISTIX approvals in Mexico, Brazil and Europe are ignored. The extraordinary Abivertinib results are never mentioned. The huge SP-102 market is overlooked.
Long term patient informed investors will do well. Sorrento is a small well funded Biotech with a large Biotech portfolio!
Sorrento Therapeutics Mexico to Partner with the World Boxing Council for the Screening of COVID-19 of all Convention Attendees with COVI-STIX at the 59th World Boxing Council Convention in Mexico City
November 12, 2021 at 3:19 PM EST
Download PDF
SAN DIEGO and MEXICO CITY, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and the World Boxing Council (“WBC”) announced today that Sorrento’s COVI-STIX COVID-19 Virus Rapid Antigen Detection Test (“COVI-STIX”) will be used for screening all attendees of the upcoming 59th World Boxing Council Annual Convention in Mexico City, Mexico (November 14th through November 18th).
The pandemic brought the world to a standstill and while most sports froze, boxing remained active through efforts by promoters, boxing commissions and the WBC. Boxing leads the world of sports in administrative and medical protocols to allow boxing matches to be held in bubbles without fans present.
Testing is and should remain a major factor for the successful organization of any public event, including boxing events with audiences present at maximum capacity.
Sorrento Therapeutics Mexico has teamed with the WBC to provide COVI-STIX rapid testing for the event and have together committed to be very active in providing solutions to the boxing industry, as well as other sports and entertainment focused events.
COVI-STIX tests will be administered to all convention attendees prior to registration and a local testing laboratory will provide testing and travel certificates to all foreign visitors requiring proof of testing for international travel.
Many superstars will be in Mexico City to attend the “Together Again” convention, including Floyd Mayweather, Julio César Chávez, Oscar De La Hoya, Larry Holmes, Roberto Durán and Antonio Tarver, among many other heroes from yesterday and today who will be in attendance, including boxing’s biggest superstar Canelo Álvarez.
For information regarding the WBC convention, please refer to WBC’s website at https://wbcboxing.com/en/info-about-wbc-convention-59/ or send an email to contact@wbcboxing.com.
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19. Sorrento's multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates (“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com.
About the World Boxing Convention (WBC)
The WBC Convention is the largest boxing convention in the world. The great and the good from every aspect of the sport attend, from boxers to referees judges, promoters, managers doctors and many more.
The annual convention unites delegates from all member-countries and key boxers from all over the world. During the convention, participants discuss topical issues, plans and future fights. Current champions often find out their rivals and the candidates for the championship title.
Rules are reviewed and grievances are heard. The convention deals with the previous 12 months and the next 12 months and all the issues of the day are heard and discussed during open sessions in a transparent and democratic process.
The World Boxing Council Convention is guided by the WBC Board of Governors from all of the World Regions and its president, Mauricio Sulaiman.
For more information, visit www.wbcboxing.com.
Forward-Looking Statements
This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding COVI-STIX; the performance capabilities of COVI-STIX; the planned use of COVI-STIX to screen convention attendees at the World Boxing Council Convention; and Sorrento’s potential position in the diagnostics industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks related to Sorrento’s and its subsidiaries’, affiliates’ and partners’ technologies and prospects and collaborations with partners, including, but not limited to risks related to COVI-STIX; risks of manufacturing and supplying COVI-STIX; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist the company in the execution of its COVID-19 product candidates’ strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento's most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento's Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.
Media and Investor Relations Contact
Dorman Followwill
Email: mediarelations@sorrentotherapeutics.com
Sorrento® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVI-STIX™ are trademarks of Sorrento Therapeutics, Inc.
SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc.
All other trademarks are the property of their respective owners.
©2021 Sorrento Therapeutics, Inc. All Rights Reserved.
Pr
Dawson James report on DYAD today(11/11/2021) mentioned Sorrento...
"Sorrento Therapeutics - the parties are continuing to negotiate the License Agreement, the terms of which may be materially different than the terms set forth in the binding term sheet announced on August 11, 2021; we can give no guidance if or when the License Agreement will be executed, but in the interim, technology transfer to Sorrento for DYAI-100 and the C1 platform has been initiated."
My guess is that there will be a wider agreement.
NASDAQ website says BLACKROCK owns 20.9 million shares of Sorrento as of 09/30/2021...a 9% increase from previous quarter. I bet they are still buying. They know a lot more than us retail investors!
I agree that any buyout attempt in the near future would be hostile. What interests me is who might be the White Knight. Sorrento pipelines in Covid, cancer and non-opioid pain would be attractive to any Large Pharma...but would also move any intermediate sized Pharma into the big leagues! We might get some hints as worldwide marketing partnerships should be announced soon for Abivertinib and Covid tests and drugs! I would not be surprised to see interest from Japanese, Korean, European as well as US firms!
We should not overlook Scilex marketing partners!
CARDINAL HEALTH. $162 Billion revenue. over 50,000 employees. 14 th highest revenue generating company in the US.
ITOCHU. over 100,000 employees.$100+ billion revenue.
Might this give us a clue as to who might market Abivertinib, Covid tests and Covid drugs around the world?
SCILEX PORTFOLIO
ZTlido® (lidocaine topical system) 1.8%
(Post-herpetic Neuralgia-PHN, Shingles pain)
Approved and Launched October 2018
SP-102
(Lumbar Radicular/Sciatica Pain)
Phase 3 trial enrollment completed in 2H 2021
SP-103
Lidocaine Topical System 5.4% (3X)(Acute Low Back Pain)
Initiating Phase 2 in 2H 2021
SP-104
Delayed Burst Release Low Dose Naltrexone (Fibromyalgia)
Initiating Phase 1 in 2H 2021
Scilex could very well be spun off. It is a company within a company. It has a marketed product, a blockbuster phase 3, other huge potential phase 2 and phase 1 products.
https://www.scilexpharma.com/
I think so.
Is COVI-AMG any good?
It is a two minute Mab injection that could compete with Pfizer and Merck anti-viral pills...but without the unknown side-effects.
When will we know if it works?
A 280 hospitalized patient study scheduled completion this October.
A 500 patient out-patient study scheduled completion this month!
COVI-AMG will not need 2-3 hour infusion center sessions like other Mabs.
It may not need to fit into a 3-5 day window like the Pfizer and Merck pills. And it is the same Mab as COVI-DROPS so the results may foreshadow the nose drop formulation results which may be even better!
COVISTIX, COVI-AMG and COVIDROPS could make a good team.
Sorrento Awarded California Competes Tax Credit
November 7, 2021 at 1:08 PM EST
SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California Governor’s Office of Business and Economic Development (“GO-Biz”). Pursuant to the Agreement, Sorrento has been awarded, subject to the satisfaction of certain milestones specified in the Agreement, an income tax credit from the State of California in an aggregate amount of up to $25,000,000. This incentivized credit is expected to support Sorrento’s vision of growth and expansion within the State of California.
"We are grateful to the State of California and GO-Biz for this award," stated Dr. Henry Ji, Chairman and CEO of Sorrento. "As a company founded in San Diego, we are pleased to be in a position to create more high-quality jobs in San Diego’s vibrant life sciences industry and invest in growing our footprint in the community we call home."
Sorrento is expanding its facilities and operations in San Diego, including the addition of a new 163,000 square-foot facility in Sorrento Mesa, also known as Sorrento Gateway.
I'm not Virginia but I too look forward to Christmas and the new year. 2022 should be a good year, in part because we will learn a lot more about what is happening in Q4 2021!
I do expect some news over the next week and look forward to the AGM November 15.
COVISTIX, COVI-AMG, COVIDROPS, COVI-MSC, ABIVERTINIB(cancer and covid) and SP-102, SP-103 and RTX all need to be updated...huge potentials. And I can think of at least 6 cancer trials I would like to see updated! But perhaps it is the Covid and cancer marketing partnerships which will be most impactful!
COVISTIX approvals in Mexico and Brazil give it access to 435 million in South America and 182 million in Central America. European CE Mark give it access to much of Greater Europe 748 million and Turkey 85 million. Sorrento is ramping up production as 4th wave spreads. New Pfizer and Merck and Sorrento drugs need rapid, accurate and affordable tests = COVISTIX!
So does USA 332 million...don't let FDA approval surprise you!
And don't forget about COVIDROPS, ABIVERTINIB and COVI-MSC!
COVIDROPS, COVI-AMG, ABIVERTINIB and COVI-MSC will be Sorrento's 1-2-3-4 punch at COVID!
We already have good news for ABIVERTINIB. COVIDROPS and COVI-AMG could come any time now. And they will be followed by COVI-MSC!
MEANWHILE COVISTIX SALES IN MEXICO, BRAZIL and EUROPE can ramp up!
The MRK pill cannot be compared to ABIVERTINIB. The pill is for early stage outpatients. ABIVERTINIB is for very ill hospitalized patients to prevent intubation , extreme illness and death!
ABIVERTINIB IS STILL NEEDED!
IT IS COVIDROPS WHICH COMPARES TO THE MRK PILL! It can be given to early stage outpatients...and what will the headlines be if it is significantly better than the MRK pill? How about...
"COVIDROPS TWICE AS GOOD AS MRK PILL!"
Do you think anyone will know about Sorrento after that!